Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1363515rdf:typepubmed:Citationlld:pubmed
pubmed-article:1363515lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1363515lifeskim:mentionsumls-concept:C1512310lld:lifeskim
pubmed-article:1363515lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:1363515lifeskim:mentionsumls-concept:C0011015lld:lifeskim
pubmed-article:1363515lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:1363515pubmed:issue6Blld:pubmed
pubmed-article:1363515pubmed:dateCreated1993-4-9lld:pubmed
pubmed-article:1363515pubmed:abstractTextCyclosporin A and verapamil are substrates for P-glycoprotein. Both agents are known to reverse multidrug resistance in cells overexpressing P-glycoprotein. In this investigation, we have examined the effects of cyclosporin A and verapamil on multidrug resistance in HL60/AR cells that lack P-glycoprotein. In addition, a correlation was sought between an alteration in plasma membrane potential as measured with cationic dye DIOC5 and overexpression of P-glycoprotein. HL60/AR cells accumulated 3 fold less daunorubicin than HL60 cells. The drug accumulation defect and drug resistance in HL60/AR cells were partially corrected by verapamil and buthionine sulfoximine. However, cyclosporin A had no detectable effect on daunorubicin accumulation or drug resistance in HL60/AR cells. The multidrug resistant P338/ADR cell line overexpressed P-glycoprotein and exhibited depolarization of plasma membrane when compared to its corresponding drug sensitive parental cell line. In contrast, HL60/AR cells lacked P-glycoprotein and plasma membrane potentials were similar to those of drug sensitive HL60 cells. These results suggest that [1] verapamil modulates daunorubicin transport by a mechanism independent of P-glycoprotein, [2] the mechanisms of reversal of multidrug resistance by verapamil and cyclosporin A are distinct, and [3] the plasma membrane depolarization in multidrug resistant cell lines that overexpress P-glycoprotein, as determined by DIOC5, may be due to an increased efflux of cationic dye by P-glycoprotein, rather than a true measurement of plasma membrane potential in multidrug resistant cells.lld:pubmed
pubmed-article:1363515pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:languageenglld:pubmed
pubmed-article:1363515pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:citationSubsetIMlld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1363515pubmed:statusMEDLINElld:pubmed
pubmed-article:1363515pubmed:issn0250-7005lld:pubmed
pubmed-article:1363515pubmed:authorpubmed-author:GuptaSSlld:pubmed
pubmed-article:1363515pubmed:authorpubmed-author:GollapudiSSlld:pubmed
pubmed-article:1363515pubmed:issnTypePrintlld:pubmed
pubmed-article:1363515pubmed:volume12lld:pubmed
pubmed-article:1363515pubmed:ownerNLMlld:pubmed
pubmed-article:1363515pubmed:authorsCompleteYlld:pubmed
pubmed-article:1363515pubmed:pagination2127-32lld:pubmed
pubmed-article:1363515pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:meshHeadingpubmed-meshheading:1363515-...lld:pubmed
pubmed-article:1363515pubmed:articleTitleLack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.lld:pubmed
pubmed-article:1363515pubmed:affiliationDivision of Basic and Clinical Immunology, University of California, Irvine 92717.lld:pubmed
pubmed-article:1363515pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1363515pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1363515lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1363515lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1363515lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1363515lld:pubmed